The $4 in San Francisco is a chance for healthcare companies to start the year off right.
Executives give high-stakes presentations to investors - and then meet with them privately - to try to convince them to invest in their companies. Often, companies will save up news to announce at the event, like clinical trial results that show a new drug is working, or good financial news.
But sometimes, the news is disappointing. That can send stocks plummeting and turn off investors. Or it can create openings for savvy investors to bet on companies at a cheap price.
These are the five biotech stocks that had big tumbles during the conference this week.
Happy hunting.
Subscribe to Business Insider's weekly healthcare newsletter $4 for all the biggest news from the J.P. Morgan Healthcare Conference.